SCHEMBL3870918

SCHEMBL3870918

COC(=O)c1cc(-c2cc(C)cs2)n(-c2ccc(C(F)(F)F)cc2)n1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS2 P35354 4/20 0.44
FAAH O00519 1/20 0.42
CA1 P00915 1/20 0.42
CA2 P00918 1/20 0.42
CA9 Q16790 1/20 0.42
CHRNA7 P36544 1/20 0.42
ALDH1A1 P00352 2/20 0.42
HPGD P15428 2/20 0.42
HTT P42858 2/20 0.42
LMNA P02545 1/20 0.42
SMN1; SMN2 Q16637 3/20 0.41
NPSR1 Q6W5P4 1/20 0.41
ADORA1 P30542 1/20 0.40
CNR1 P21554 1/20 0.40
CNR2 P34972 1/20 0.40
PTGS1 P23219 2/20 0.39
EPHX2 P34913 1/20 0.39
HDAC3 O15379 1/20 0.39
HDAC4 P56524 1/20 0.39
HDAC1 Q13547 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3866697 0.89 SMN1; SMN2 (0.46) PTGS2FAAHCA1CA2CA9
SCHEMBL3865153 0.88 PTGS2 (0.56) PTGS2CA1CA2CA9CHRNA7
SCHEMBL3863718 0.86 RPA1 (0.50) PTGS2FAAHCA1CA2CA9
SCHEMBL3873187 0.86 SMPD1 (0.51) PTGS2CA1CA2CA9SMN1; SMN2
SCHEMBL3863677 0.86 SMN1; SMN2 (0.56) PTGS2FAAHCHRNA7SMN1; SMN2
SCHEMBL3876521 0.85 SMN1; SMN2 (0.46) PTGS2FAAHALDH1A1HPGDSMN1; SMN2
SCHEMBL3870130 0.83 KDM1A (0.43) PTGS2SMN1; SMN2
SCHEMBL3865218 0.80 ALDH1A1 (0.44) PTGS2ALDH1A1HPGDHTTLMNA
SCHEMBL3865539 0.78 CHRNA7 (0.41) PTGS2FAAHCA1CA2CA9
SCHEMBL5311716 0.77 CNR1 (0.47) PTGS2FAAHCHRNA7ALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090005350-A1 CYCLOOXYGENASE-2 SELECTIVE INHIBITORS, COMPOSITIONS AND METHODS OF USE NITROMED, INC. (US) 2009-01-01 US disclosed
US-7442802-B2 Cyclooxygenase-2 selective inhibitors, compositions and methods of use NITROMED, INC. (US) 2008-10-28 US disclosed
US-20060194861-A1 Cyclooxygenase-2 selective inhibitors, compositions and methods of use NITROMED, INC. (US) 2006-08-31 US disclosed
US-7087630-B2 Cyclooxygenase 2 selective inhibitors, compositions and methods of use NITROMED, INC. (US) 2006-08-08 US disclosed
US-20040053985-A1 Cyclooxygenase-2 selective inhibitors, compositions and methods of use NITROMED, INC. 2004-03-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040053985-A1 Cyclooxygenase-2 selective inhibitors, compositions and methods of use PTGS2, PTGIS, PTGES2 PTGS2 1/4885FAAH 114/4885CA1 3581/4885
US-20060194861-A1 Cyclooxygenase-2 selective inhibitors, compositions and methods of use PTGS2, PTGIS, PTGES2 PTGS2 1/4885FAAH 114/4885CA1 3581/4885
US-20090005350-A1 CYCLOOXYGENASE-2 SELECTIVE INHIBITORS, COMPOSITIONS AND METHODS OF USE PTGS2, PTGIS, PTGES2 PTGS2 1/4885FAAH 114/4885CA1 3581/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.